Amendments to the Claims:

Please enter the following amendments to the claims, with insertions indicated by underlining and deletions by strikethrough.

1-43. (Canceled)

44. (Withdrawn) A method for treating human medullary thyroid carcinoma comprising administering to a subject a composition according to claim 113.

45-49. (Canceled)

50. (Withdrawn) A method of treating human colorectal cancer comprising administering to a subject a composition according to claim 113.

51-112. (Canceled)

113. (Previously presented) A composition comprising:

a) a naked humanized MN-14 (hMN-14) antibody comprising light chain variable region CDR sequences CDR1 (KASQDVGTSVA, SEQ ID NO: 20); CDR2 (WTSTRHT, SEQ ID NO: 21); and CDR3 (QQYSLYRS, SEQ ID NO: 22); and heavy chain variable region CDR sequences CDR1 (TYWMS, SEQ ID NO: 23); CDR2 (EIHPDSSTINYAPSLKD, SEQ ID NO: 24); and CDR3 (LYFGFPWFAY, SEQ ID NO: 25) and human framework region sequences and an IgG1 human constant region, wherein administration of the naked hMN-14 antibody to a cancer expressing CEA sensitizes the cancer to administration of an apoptosis agent selected from the group consisting of DTIC and CPT-11; and

b) an apoptosis agent selected from the group consisting of DTIC and CPT-11, wherein the combination of the naked hMN-14 antibody and the apoptosis agent is more effective for treatment of human medullary thyroid carcinoma or human colorectal cancer than either the naked anti-CEA MAb or the apoptosis agent alone or the sum of the effects of the naked anti-CEA MAb and the apoptosis agent administered individually.

114-116. (Canceled)

117. (Previously presented) The composition of claim 113, further comprising a therapeutic agent.

118. (Previously presented) The composition of claim 117, wherein the therapeutic agent is selected from the group consisting of another naked antibody, a cytotoxic agent, a drug, a radionuclide, an immunomodulator, a photoactive therapeutic agent, an immunoconjugate and a hormone.

119. (Previously presented) The composition of claim 118, wherein the drug is selected from the group consisting of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, anthracyclines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antimetabolites, antibiotics, epipodophyllotoxins, platinum coordination complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, endostatin, taxols, camptothecins, oxaliplatin and doxorubicin.

120. (Previously presented) The composition of claim 118, wherein the cytotoxic agent is a toxin selected from the group consisting of ricin, abrin, alpha toxin, saporin, ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtheria toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.

121. (Previously presented) The composition of claim 118, wherein the immunomodulator is selected from the group consisting of a cytokine, a stem cell growth factor, a lymphotoxin, a hematopoietic factor, a colony stimulating factor (CSF), an interferon (IFN), a tumor necrosis factor (TNF) and an interleukin (IL).

122. (Previously presented) The composition of claim 118, wherein the radionuclide is selected from the group consisting of ^{32}P, ^{33}P, ^{47}Sc, ^{59}Fe, ^{64}Cu, ^{67}Cu, ^{75}Se, ^{77}As, ^{89}Sr, ^{90}Y, ^{99}Mo, ^{105}Rh, ^{109}Pd, ^{111}Ag, ^{125}I, ^{131}I, ^{142}Pr, ^{143}Pr, ^{149}Pm, ^{153}Sm, ^{161}Tb, ^{166}Ho, ^{169}Er, ^{177}Lu, ^{186}Re, ^{188}Re, ^{189}R, ^{194}Ir, ^{198}Au, ^{199}Au, ^{211}Pb, ^{212}Pb, ^{213}Bi, ^{58}Co, ^{67}Ga, ^{80m}Br, ^{99m}Tc, ^{103m}Rh, ^{109}Pt, ^{111}In, ^{119}Sb, ^{161}Ho, ^{189m}Os, ^{192}Ir, ^{152}Dy, ^{211}At, ^{212}Bi, ^{223}Ra, ^{219}Rn, ^{215}Po, ^{211}Bi, ^{225}Ac, ^{221}Fr, ^{217}At, ^{88}Y and ^{255}Fm.

123. (Previously presented) The composition of claim 121, wherein the immunomodulator is selected from the group consisting of erythropoietin, thrombopoietin, TNF-α, IL-l, IL-2, IL-3, IL-6, IL-l0, IL-12, IL-18, IL-21, granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-α, interferon–ß, interferon-γ and a stem cell growth factor designated "S1 factor.